References
- Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. European Journal of Cancer 2004; 40: 939–950
- Teixeira L, Barry S, Debourdeau P, Cohen A, Tournigand C. Cardiotoxicity of 5-fluorouracil. Bulletin du Cancer 2004; 91: 154–158
- Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. American Journal of Clinical Oncology 1998; 21: 248–249
- Sucker C, Lambers C, Stockschlader M, Dolken G. Neurotoxicity of 5-fluorouracil. Deutsche medizinische Wochenschrift 2002; 127: 2011–2014
- Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anti-cancer Drugs 2001; 12: 525–531
- Van Laarhoven HW, Verstappen CC, Beex LV, Kappelle AC, Punt CJ. 5-FU-induced peripheral neuropathy: a rare complication of a well-known drug. Anticancer Research 2003; 23: 647–648
- Saletti P, Pagani O, Sessa C, Goldhirsch A. Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration. Annals of Oncology 1996; 7: 213–214
- Shehata N, Pater A, Tang SC. Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Cancer Investigation 1999; 17: 201–205
- Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clinical Cancer Research 1996; 2: 477–481
- Delval L, Klastersky J. Optic neuropathy in cancer patients. Report of a case possibly related to 5-fluorouracil toxicity and review of the literature. Journal of Neuro-oncology 2002; 60: 165–169
- Rowin J, Meriggioli MN. Electrodiagnostic significance of supramaximally stimulated A-waves. Muscle & Nerve 2000; 23: 1117–1120